The Effect of Cannabidiol for Restless Legs Syndrome/Willis-Ekbom Disease in Parkinson's Disease Patients with REM Sleep Behavior Disorder: A Post Hoc Exploratory Analysis of Phase 2/3 Clinical Trial.
Cannabis Cannabinoid Res
; 8(2): 374-378, 2023 04.
Article
en En
| MEDLINE
| ID: mdl-35749710
ABSTRACT
Background:
Cannabidiol (CBD) is one of the main nonpsychoactive components of Cannabis sativa and may represent an alternative treatment for Restless Legs Syndrome/Willis-Ekbom Disease (RLS/WED) in patients with Parkinson's disease (PD) and REM (Rapid Eye Movement) sleep behavior disorder (RBD).Objective:
Our purpose was a post hoc exploratory analysis to evaluate the CBD's efficacy to improve the severity of RLS/WED symptoms in patients with PD and RBD.Methods:
A post hoc exploratory analysis of a phase II/III, a parallel, double-blind, placebo-controlled clinical trial was conducted in 18 patients with RLS/WED and PD plus RBD associated. Six patients were randomized to the CBD group in doses of 75-300 mg, and twelve received placebo capsules. They were followed up for 14 weeks. The primary outcome was the severity of RLS/WED by Restless Legs Syndrome Rating Scale of the International Restless Legs Syndrome Study Group (IRLSSG).Results:
CBD showed no difference in relationship to placebo for primary and secondary outcomes.Conclusion:
CBD showed no reduction in the severity of RLS/WED manifestation in patients with PD and RBD.Palabras clave
Texto completo:
1
Banco de datos:
MEDLINE
Asunto principal:
Enfermedad de Parkinson
/
Síndrome de las Piernas Inquietas
/
Cannabidiol
/
Cannabis
/
Trastorno de la Conducta del Sueño REM
Tipo de estudio:
Clinical_trials
Límite:
Humans
Idioma:
En
Año:
2023
Tipo del documento:
Article